P ulmonary hypertension (PH) is a hemodynamic and pathophysiological state defined as increased mean pulmonary artery pressure ≥25 mm Hg at rest (assessed by right heart catheterization [RHC]).
on RHC or improved exercise capacity (increase in 6MWD) in randomized controlled trials. [8] [9] [10] [11] [12] [13] [14] [15] Consequently, disease progression and treatment efficacy in the clinic are frequently assessed using 6MWD or RHC. Recent interest in the RV and its response to change in afterload 16, 17 has raised the possibility that direct assessment of RV function may be a more appropriate way of determining response to therapy and monitoring disease progression.
Noninvasive cardiac MRI (CMRI) provides a comprehensive picture of RV structure and function because it has unparalleled resolution, is reproducible, can provide 3-dimensional images, has the ability to depict soft tissues, and can be conducted in patients not suitable for echocardiography. 18 CMRI also has benefits over RHC and is considered to be the gold standard for assessment of RV volume, mass, and function. However, uptake of CMRI in clinical practice has been limited, and although this may be partly attributable to cost, lack of published data showing its use in patients with PH, especially in those receiving treatment, may also contribute. This pan-European study of patients with PH evaluated RV function using CMRI during treatment of patients with PH.
Methods
As part of the EU Framework 6 Pulmotension initiative, the prospective, longitudinal European Magnetic Resonance Imaging Study in PAH study was conducted in 4 European centers: Scottish Pulmonary Vascular Unit, Glasgow, United Kingdom; Medical University Graz, Graz, Austria; Sapienza University of Rome, Rome, Italy; and Department of Pulmonary Medicine, VU University Medical Center, Amsterdam, The Netherlands. The aim of this initiative was to determine RV function changes during disease-specific therapy. The initiative complied with the widely recognized guidelines for conducting studies in humans. The study was approved by an institutional review committee, and all subjects provided written, informed consent.
Between June 2003 and May 2010, patients with suspected PH were referred to their local PH center for evaluation. Patients underwent clinical assessment, including New York Heart Association (NYHA) FC, RHC, 6MWD, and CMRI. PH was diagnosed and classified according to current guidelines 1 and, if appropriate, diseasetargeted therapy was initiated. 19 The initial therapy used was left to the discretion of the local PH physician. The 12-month follow-up evaluation assessment included 6MWD and CMRI. Patients from the Glasgow center also had a planned assessment (6MWD and CMRI) after 4 months of treatment.
Patients in World Health Organization (WHO) group 1, WHO group 3, or WHO group 4, if ineligible for surgery, were included in the study. Patients excluded from the analysis included those unable to attend or who declined follow-up evaluation; those who were not commenced on disease-targeted therapy after initial evaluation; those with no evidence of PH at RHC; those with PH associated with left heart disease (WHO group 2); and those previously treated with disease-targeted therapy.
Clinical Assessment
The 6-minute walk test was performed at each center according to the American Thoracic Society guidelines. 20 RHC was performed at each center according to international recommendations. 1 This typically involved the use of a 7F triple-channel thermodilution Swan-Ganz catheter (Baxter Healthcare; Irvine, CA). All measurements were recorded with the patient in a supine position, at rest, and breathing room air. Hemodynamic variables, including pulmonary artery pressure and pulmonary artery occlusion pressure, were recorded from the traces. Cardiac output was determined using thermodilution, allowing the calculation of pulmonary vascular resistance ([mean pulmonary artery pressure−pulmonary artery occlusion pressure]/cardiac output).
CMRI Assessment
CMRI was performed locally using a 1.5-T MRI scanner (Sonata Magnetom, Siemens; Erlangen, Germany) using an agreed protocol described previously. 21 Individual scans were coded by number and analyzed centrally in Glasgow, United Kingdom. All scans were read in a blinded fashion by 1 of 3 observers on a single MR work station using Argus analysis software (Siemens; Erlangen, Germany). The reproducibility and reliability of the observer's tracing were assessed by computing the interobserver and intraobserver variability (presented as the mean±SD of the differences between 2 estimations) for the LV and RV measurements. In these retrospective calculations, 24 and 10 CMRI examinations from the Glasgow center were randomly selected to determine interobserver variability and intraobserver variability, respectively. For the intraobserver data, scans were reanalyzed, blinded to the initial results.
RV and LV volumes (RV end-diastolic volume [RVEDV], RV end-systolic volume, LV end-diastolic volume [LVEDV] , and LV end-systolic volume) were determined by manual planimetry as described previously. 22 RV and LV stroke volumes, RV and LV ejection fractions (RVEF and LVEF), and RV and LV mass were determined as previously described. 22 RV mass was determined as RV free wall mass, and the interventricular septum was considered part of the LV. Ventricular mass index was determined as RV mass/LV mass. 23 RV and LV volumes and mass were indexed to body surface area.
Statistical Analysis
For all variables, a normal distribution was verified using histograms and Kolmogorov-Smirnov tests. For demographic, hemodynamic, and CMR variables, mean±SD were calculated. For the entire cohort, comparison between baseline and 12-month follow-up was performed using the paired t test. A repeated measure 1-way ANOVA was used to compare the mean values in the smaller Glasgow subgroup. A significance level of 5% was used in all tests. All calculations were performed using GRAPHPAD Prism (Version 5.00; GraphPad Software Inc; La Jolla, CA). All values in the subsequent results and discussion sections are presented as mean±SD unless otherwise stated. Variability analyses were compared using Bland-Altman analysis and t tests.
The correlation between the change in CMRI variables and 6MWD as determined by Pearson correlation was also conducted and is provided in the Data Supplement.
Results
RHC was conducted in 107 patients with suspected PH, which was confirmed in 91 patients (Glasgow: 35; Amsterdam: 26; Rome: 17; and Graz: 13); these patients underwent assessment at baseline and after 12 months of disease-targeted therapy. Baseline characteristics for the entire cohort and by study center are summarized in Table 1 . Most patients (n=71) were in WHO group 1 and had significant PH at baseline RHC. Baseline characteristics of the subgroups are provided in the Data Supplement. Medical therapy initiated at baseline is shown in Table 1 , with endothelin receptor antagonist monotherapy being the most frequently used treatment.
An additional clinical and CMRI assessment was performed after 4 months of disease-targeted therapy in 27 of the 35 patients from Glasgow (Table 1) . There was a significant increase in 6MWD after 12 months of disease-targeted therapy (381±127 m at baseline, 443±124 m at month 12; P<0.0001). At the 12-month follow-up, 5, 46, 36, and 4 patients were in NYHA FC I, II, III, and IV, respectively. FC improved in 21 patients, was unchanged in 63 patients, and deteriorated in 7 patients.
CMRI Assessment
CMRI characteristics at baseline and after 12 months of disease-targeted therapy in the whole group (n=91) are summarized in Table 2 and provided for each study center in the Data Supplement. After 12 months of therapy, there were significant increases in RVEF (40.5±16.0% at baseline, 45.2±14.7% at month 12; P<0.0001) and RV stroke volumes index (31.0±8.4 mL/m 2 at baseline, 35.9±9.3 mL/m 2 at month 12; P<0.0001). Significant improvements were also noted in LVEDV index (48.4±12.9 mL/m 2 at baseline, 52.5±14.1 mL/m 2 at month 12; P=0.0015) and LVEF (66.7±11.7% at baseline, 70.3±9.8% at month 12; P=0.0007). Overall, there was no improvement or deterioration in the degree of RV dilatation (RVEDV index) or RV hypertrophy (ventricular mass index). Similar results were obtained from subanalyses of patients with PAH or when data were stratified according to baseline PAH therapy (Table 3) .
Glasgow Subgroup Analysis
The improvements in clinical and CMRI characteristics measured at 12 months were present at 4 months in the Glasgow subgroup (Table 4) . 6MWD increased significantly throughout the study (Figure 1 ; P<0.0001). There were also early improvements in RVEF and stroke volume index that were preserved at 12 months (Table 4) . A similar pattern of improvement was observed in LVEDV 6MWD indicates 6-minute walk distance; CTEPH, chronic thromboembolic pulmonary hypertension; IPAH, idiopathic PAH; NYHA, New York Heart Association; PAH, pulmonary arterial hypertension; PAH-CHD, PAH associated with congenital heart disease; PAH-CTD, PAH associated with connective tissue disease; PAP, pulmonary artery pressure; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; and WHO, World Health Organization.
*Data provided for patients with a clinical and cardiac MRI assessment conducted at 4 months. †One patient in the Graz subgroup was in WHO group 5. ‡PAH associated with HIV infection (n=1), PAH associated with hypoxic lung disease (n=1), heritable PAH (n=2), and drug and toxin-induced PAH (n=2).
index and LVEF. There was no overall improvement or deterioration in RV hypertrophy or RV dilatation. Analysis of interobserver variability in a subgroup of patients from the Glasgow center demonstrated lower interobserver variability for LV measures than for those in the RV (Table   III in the Data Supplement). Intraobserver variability was low for volume measurements (EDV, stroke volume, and EF) but higher for mass measurements (Table IV in the Data Supplement). Variability was lower for the LV than for the RV. 
Association of CMRI Variables With 6MWD
Significant correlations were seen between change in 6MWD and change in RVEF and LVEDV, although correlation coefficients were low ( Figure 2 ).
Discussion
This is the first multicenter study to prospectively assess the use of CMRI before and during PAH disease-specific therapy. It demonstrated that both left-sided and right-sided variables should be included when assessing cardiac function in patients with precapillary PH. In the current analysis, stroke volume index, cardiac index, and EF were associated with response when measured in either the left or the right heart. LVEDV index was also associated with therapeutic response. In the past, there has been evidence that the initial benefits achieved with some disease-targeted therapies are not maintained during longterm treatment; 24 however, the data from the Glasgow cohort demonstrate that the improvement in stroke volume index, cardiac index, and EF at month 4 was still present at month 12.
The current study is the most comprehensive to date, investigating the use of CMRI during treatment of patients with PH, and supports the data from several smaller trials studying changes in CMRI-derived variables during treatment. The Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study demonstrated that RV mass decreased significantly from baseline after 16 weeks of sildenafil treatment (n=13; P=0.015); 25 although this was not observed in the 12 patients receiving bosentan, for whom there was no significant difference between treatments (P=0.142). Similarly, addition of sildenafil to background bosentan therapy reduced RV mass, which may be explained either by reduced RV wall stress or by an intrinsic effect on the heart. 26 In a small single-center study, a trend toward a treatment (bosentan)-related effect on stroke volume index was seen, and there was no effect on RVEF, LVEDV, or RVEDV. 27 This study highlighted the need for further investigation of CMRI variables associated with RV function and how they relate to variables such as 6MWD. It has also been shown previously that epoprostenol therapy lowered pulmonary vascular resistance but did not affect RV dilatation or hypertrophy. 28 A key advantage of this multicenter analysis was that it provided an opportunity to study the consistency of the findings in several subanalyses. Although the number of patients in each center was small and the analysis was not powered for comparison, at the majority of centers, there was a trend toward improvement or at least no deterioration in the CMRI variables significantly associated with therapeutic response in the main analysis. Similarly, when stratified for baseline PAH therapy, the same variables were identified, and despite the small numbers, statistical significance was achieved. These findings demonstrate the wide applicability of CMRI for following up patients with PH. Several therapeutic options are now available for management of patients with PAH, and prescription patterns vary between countries. In this analysis, identification of patients suitable for therapy was at the discretion of the physician, which can be seen as both a strength and limitation of the study. Because the results obtained reflect real clinical practice, the findings are likely to be pertinent for other treatment centers and may also provide insight into different treating practices. However, differences between treatments cannot be determined because the study was not designed to collect data on changes in therapy during the study duration, which is a limitation. However, the consistency of the findings when stratified by baseline PAH-specific therapy suggests that although acting via different pathways, the net effect of these treatments on pulmonary vasculature and RV function will be similar.
The use of 6MWD as a surrogate marker of outcome (in particular, mortality and morbidity) has been questioned in several recent studies. To meet the criteria as a surrogate, it needs to provide a reliable replacement for the outcome measure. A recent pooled analysis of data from 10 randomized controlled trials of PAH-specific therapies showed that although the change in 6MWD from baseline to week 12 was a mediator of the relationship between treatment and the development of a clinical event, it accounted for <25% of the total relationship. 29 The findings of our analysis confirmed that the correlations between 6MWD and CMRI variables were weak.
It is well established that RV function is associated with outcome in patients with PAH. Factors relating to the dynamic function of the right heart (in particular, stroke volume and EF) seem to be the most linked to outcome. However, some left heart variables are known to better correlate with overall cardiac function than RV function in patients with PH. For example, LV end-diastolic volume is more closely related to stroke volume than RVEDV. 30 This is supported by data from echocardiography studies in patients with PH that demonstrated that eccentricity index, which include LV size, is closely associated with outcome in PAH, whereas RVEDV is not. 31 Several groups have also demonstrated that poor LV output in PH is related to poor filling of the LV. 21 This underfilling of the LV, a consequence of poor filling on the left side because of prolonged RV contraction time, 32 contributes to decreased SV. 33 For this reason, it is likely that LVEDV may be a particularly important variable because it reflects both SV and increased RV contraction time. These findings highlight the importance of LV volume measurements in patients with PH.
Echocardiography is the most frequently used noninvasive technique used to assess RV function and provides a comprehensive assessment of right heart performance. The evaluation is based on the assessment of tricuspid annular plane systolic excursion, LV eccentricity index, and degree of tricuspid regurgitation. 34 However, well-described limitations of echocardiography include the inability to accurately estimate RV mass or volume as a result of the complex geometry of the RV. Radionuclide imaging, 35 RHC, 36 or measuring levels of N-terminal B-type natriuretic peptide, 37, 38 possibly as a marker of intravascular overload rather than a direct marker of RV function, all provide ways of measuring RV function but are either invasive or less comprehensive than CMR or both. CMRI is superior to radionuclide imaging because it does not require ionizing radiation and superior to electrocardiography because it is more sensitive. 39 There is also some evidence to suggest that N-terminal B-type natriuretic peptide measurements reflect changes in CMRI-determined RV structure and function in patients with PH, 33, 39 but the potential of this noninvasive marker as a surrogate for outcome remains to be demonstrated. 40 The study had some limitations. The number of patients was low compared with the time span of enrollment, and this is because only a proportion of consecutive patients underwent CMRI, which could have been a result of either concerns of the patient about claustrophobia or technical problems. The inclusion criteria allowed a heterogeneous population of patients with PH to be enrolled, and, unlike previous studies, it was not restricted to patients with PAH. Although diseasespecific therapy is only recommended in management guidelines for PAH, 1 in clinical practice, these treatments are also used in WHO groups 3, 4, and 5. There was also the potential for analysis of the CMRI scans to vary between the centers; however, containing the reading of the scans to a single laboratory with a small number of observers ensured that a uniform technique for measurements and reporting was used. As demonstrated in the small subanalysis, both interobserver and intraobserver variability were low, although variability was higher in RV analyses than in those involving the LV. This reflects planimetry of the RV being more challenging than planimetry of the LV. Other variables that may be important prognostically and therapeutically were not included in the current analysis. These include pulmonary artery stiffness, pulmonary perfusion, and RV arterial coupling. Clearly, these are important variables and, as measurement techniques improve, will become part of the armory of CMRI-derived measurements used to study patients with PAH. Although it would have been valuable to determine the relationship between the CMRI variables and patient outcome, outcome data were not collected in this study, and retrospective analysis is therefore not feasible. Future studies are required to determine whether the CMRI variables identified are associated with patient outcome.
In conclusion, this multicenter study demonstrated that the detailed CMRI assessments at baseline and during follow-up conducted in this patient cohort provide valuable information about response to PAH-specific therapy. The robust and noninvasive nature of CMRI means that the results of this study should be considered when designing future studies in PH so that CMRI variables are included as indicators of therapeutic response.
